[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-hyperparathyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-hyperparathyroidism":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,48,81,105,131,158,187,210,238,266,286,305,327],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100436950","natural-history-study-of-parathyroid-disorders-100436950",false,"NCT04969926","Natural History Study of Parathyroid Disorders","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Subjects known to have, suspected of having, or at risk of developing a parathyroid or related disorder.\n* Age \\>= 6 months.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Children \\\u003C= 6 months\n* Patients with conditions that in the opinion of the investigators can interfere with the study objectives.","ALL","6 Months","100 Years",{"count":19,"type":20},3000,"ESTIMATED","OBSERVATIONAL","Background:\n\nParathyroid disorders are very common in the general population and include disorders of parathyroid excess, deficiency, or defects in parathyroid hormone (PTH) signaling. PTH, the main secretory product of parathyroid glands is responsible for regulation of calcium-phosphate homeostasis.\n\nObjective:\n\ni) To investigate the cause of parathyroid disorders\n\nii) To describe evolution, natural history, and longitudinal trends of parathyroid and related disorders seen in syndromic presentations like multiple endocrine neoplasia, hyperparathyroidism-jaw tumor syndrome\n\nEligibility:\n\nPeople ages 6 months older who have, are at risk of having, or are related to a person with a parathyroid or related disorder.\n\nDesign:\n\nParticipants will be screened with a review of their medical records.\n\nParticipants will be seen, tested, and treated by doctors based on their condition. Their visits may be in person or via telehealth.\n\nParticipants will complete questionnaires. They will answer questions about their physical, mental, and social health.\n\nParticipants may give samples such as saliva, blood, urine, or stool.\n\nParticipants may give cheek cell samples. They will do this using a cheek swab or by spitting into a cup.\n\nAdult participants may give a skin biopsy. For this, a small bit of skin is removed with a punch tool.\n\nParticipants may have medical photos taken.\n\nIf participants have surgery during the course of their regular care either at the NIH\n\nor at a different hospital or doctor s office, researchers will ask for some of the leftover\n\ntissue.\n\nParticipants will be in the study as long as they are being seen by their doctor.",[24,25,26,27,28],"Parathyroid Cancer","Primary Hyperparathyroidism","Pseudohypoparathyroidism","Inheritable Bone Diseases","Multiple Endocrine Neoplasia, Type 1",[30,31,24,32,33,34],"Hyperparathyroidism","calcium disorders","Inheritable","PSEUDOHYPOPARATHYROIDISM","Natural History","RECRUITING","2026-06-19",{"date":38,"type":39},"2026-06-23","ACTUAL",{"date":41,"type":39},"2021-11-30",{"date":43,"type":20},"2031-01-22",{"name":45,"class":46},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100627137","phase-2-accuracy-of-18f-fluorocholine-petmr-and-neuroexplorer-petct-imaging-for-localization-of-parathyroid-tumors-100627137","NCT07444723","Accuracy of 18F-Fluorocholine PET\u002FMR and NeuroEXPLORER PET\u002FCT Imaging for Localization of Parathyroid Tumors","A Phase II Study of Accuracy of 18F-Fluorocholine PET\u002FMRI and NeuroEXPLORER PET\u002FCT Imaging for Localization of Parathyroid Tumors","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all the following criteria:\n\n1. Aged 18-100 years old\n2. Willing to have parathyroidectomy at NIH Clinical Center\n3. Meets one of the following:\n\n   1. Diagnosed with sporadic PHPT and is a potential candidate for parathyroidectomy.\n   2. Diagnosed with any forms of heritable primary hyperparathyroidism (index presentation or recurrent disease) and is a potential candidate for parathyroidectomy. Participants clinically suspected of multi-gland disease (individuals with secondary\u002Ftertiary hyperparathyroidism) or germline predisposition PHPT syndrome are included in this cohort\n   3. Suspected to have, or diagnosed with, parathyroid cancer and is a potential candidate for parathyroidectomy.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnancy or lactation\n2. Known allergic reactions to components of the 18F-Fluorocholine radiopharmaceutical.\n3. For persons able to become pregnant: unwilling to use highly effective contraception for at least two weeks prior to date of the first imaging scan through the date of the parathyroidectomy surgery\n4. Use of any investigational product or device, excluding F-DOPA scans, within 30 days prior to the 18F-FCH scan.\n5. Unable or unwilling to provide informed consent.\n6. Any other condition that would prevent the safe completion of study participation in the clinical opinion of the investigators.","18 Years",{"count":57,"type":20},193,"INTERVENTIONAL",[60,61],"PHASE2","PHASE3","Background:\n\nPeople have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with contrast dye to help find them before surgery. Researchers want to know if a different type of scan and a new tracer can make it easier to find the tumors in the parathyroid glands.\n\nObjective:\n\nTo see if PET\u002FMRI and NeuroEXPLORER PET-CT scans with a 18F-FCH tracer are better than existing methods for finding the parathyroid glands.\n\nEligibility:\n\nPeople aged 18 years or older who are scheduled for surgery to remove a parathyroid gland.\n\nDesign:\n\nParticipants will have up to 4 clinic or hospital visits. They will be screened. They will have a physical exam and give blood samples.\n\nParticipants will have a 4-dimensional computed tomography (4D-CT) scan. This is the current way doctors look for parathyroid glands. They will be injected with an iodine-based dye for the 4D-CT scan. They will lie on a padded table that slides into a donut-shaped machine.\n\nParticipants will have a positron emission tomography (PET)-magnetic resonance imaging (MRI) and NeuroEXPLORER PET-CT scan. For these scans, they will be injected with a radioactive tracer (18F-FCH). They will wait about 30 to 60 minutes for their body to absorb the tracer. They will lie on a padded table that slides into a tube. Their vital signs will be monitored during the scan.\n\nParticipants will have surgery to remove the target gland. They may need to stay in the hospital for up to 3 nights.\n\nParticipants will have a follow-up visit 6 months after the surgery. This may be done remotely....",[25,24,64,65,66],"Multiple Endocrine Neoplasias","Heritable Hyperparathyroidism","Hyperparathyroid-jaw Tumor Syndrome",[68,24,69,70,71,72],"Primary hyperparathyroidism","MEN1","Heritable hyperparathyroidism","Hyperparathyroid-jaw tumor syndrome","Parathyroid adenomas","2026-05-30",{"date":75,"type":39},"2026-06-02",{"date":77,"type":39},"2026-04-16",{"date":79,"type":20},"2036-02-05",{"name":45,"class":46},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":47},"100288799","molecular-and-immunohistochemical-profiling-of-tumors-in-patients-with-parathyroid-tumors-100288799","NCT03039439","Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors","Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents","Inclusion Criteria:\n\n* The patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or the appropriate external mechanism for collaborating sites).\n* All patients with a known diagnoses of primary hyperparathyroidism (PHPT) operated\u002Ftreated in the Department of Surgical Oncology of MDACC or at a collaborating site. Patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate external mechanism for collaborating sites).\n* All consented patients with known diagnoses of PHPT with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There will be no restrictions on age, gender, or ethnicity.\n* Selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study.\n\nExclusion Criteria:\n\n* Patients without tissue available for analysis.",{"count":89,"type":20},310,"This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.",[92,93,94,25],"Parathyroid Gland Adenoma","Parathyroid Gland Atypical Adenoma","Parathyroid Gland Carcinoma","2026-05-19",{"date":97,"type":39},"2026-05-22",{"date":99,"type":39},"2015-11-24",{"date":101,"type":20},"2028-11-30",{"name":103,"class":104},"M.D. Anderson Cancer Center","OTHER",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":113,"minAge":55,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100515922","parathyroid-tumor-clonal-status-100515922","NCT05997810","Parathyroid Tumor Clonal Status","A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Hyperparathyroid Disorders (Primary, Secondary, and Tertiary)","Inclusion Criteria:\n\n* 1\\. Diagnosed with hyperparathyroidism (primary, secondary, or tertiary), biochemically confirmed (e.g., serum calcium and\u002For intact PTH consistent with the underlying etiology), and undergoing clinically indicated management\n* Female and male patients\n* Age ≥ 18 years\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* Patients with a history of cervicofacial irradiation.\n* Patients currently taking lithium or with a history of lithium use.\n* Pregnant patients",true,"FEMALE","80 Years",{"count":116,"type":20},839,"To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).",[119,25,120,121],"Parathyroid Tumor","Secondary Hyperparathyroidism (SHPT)","Tertiary Hyperparathyroidism","2026-05-07",{"date":124,"type":39},"2026-05-12",{"date":126,"type":39},"2023-07-28",{"date":128,"type":20},"2032-01-31",{"name":130,"class":104},"Washington University School of Medicine",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":17,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":47},"100622845","aldosterone-variations-in-patients-with-primary-hyperparathyroidism-after-surgery-100622845","NCT07388914","Aldosterone Variations in Patients With Primary Hyperparathyroidism After Surgery","Aldosterone Variations in Patients With Primary Hyperparathyroidism Before Surgery and in the Year Following Surgery for Parathyroid Disease.","ALDOPARA2","Inclusion Criteria:\n\n* patients with primary hyperparathyroidism candidate to surgery\n* age\\>\u002F=18 years\n\nExclusion Criteria:\n\nage\\\u003C 18 years patients with renal insufficiency (CKDEpi \\\u003C60ml\u002Fmn) pregant women\n\n\\-",{"count":140,"type":20},400,"Primary hyperparathyroidism is a disorder of calcium and phosphorus metabolism linked to dysfunction of one or more parathyroid glands. The latest recommendations from the American Association of Endocrine Surgeons (7) consider the presence of hypertension as an argument for proposing the removal of a parathyroid adenoma in the context of primary hyperparathyroidism. The renin-angiotensin-aldosterone system is involved in regulating blood pressure.\n\nThe main objective of this study is to assess aldosterone level in patients with primary hyperparathyroidism before surgery and its variation in the year following surgery for parathyroid disease.\n\nSecondary objectives are to assess aldosterone variations after surgery at 3 months\n\n* Assess aldosterone variations after surgery at 6 months\n* Assess aldosterone variations after surgery at 12 months\n* Blood pressure changes before and after surgery (5 pre- and post-operative measurements)\n* Assess the number of antihypertensive treatments before and after surgery\n* Assess antihypertensive treatment according to the WHO-DDD classification before and after surgery Compare aldosterone levels in the 'primary hyperparathyroidism' group with a control group of patients from the general population (using the STANISLAS cohort).\n\n  * Compare aldosterone levels in the HPT group with aldosterone levels in a group of patients after myocardial infarction (cardiovascular patient group )",[25,143],"Primary Hyperparathyroidism Due to Adenoma",[145,146,147],"aldosteron","primary hyperparathyrodism","hypertension","NOT_YET_RECRUITING","2026-01-27",{"date":151,"type":39},"2026-02-05",{"date":153,"type":20},"2026-02-01",{"date":155,"type":20},"2027-02",{"name":157,"class":104},"Central Hospital, Nancy, France",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":112,"sex":15,"minAge":55,"maxAge":164,"enrollmentInfo":165,"targetDuration":167,"studyType":21,"phases":4,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100622118","amino-acid-transporter-system-petct-imaging-in-aats-related-diseases-100622118","NCT07379463","Amino Acid Transporter System PET\u002FCT Imaging in AATS-Related Diseases","Inclusion Criteria:\n\n1. adult patients (aged 18 years or order);\n2. patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report);\n3. patients who had scheduled AATS PET\u002FCT scan;\n4. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n1. patients with non-malignant lesions;\n2. patients with pregnancy;\n3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","90 Years",{"count":166,"type":20},500,"7 Days","To evaluate the potential usefulness of 11C\u002F18F-MET\u002FFET positron emission tomography\u002F computed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various amino acid transporter system (AATS)-related disease patients.",[170,25,171],"Amino-Acid Transport Disorder","Glioma",[173,174,175,176],"PET\u002FCT","Amino acid transporter","MET","FET","2026-01-23",{"date":179,"type":39},"2026-01-30",{"date":181,"type":39},"2013-08-29",{"date":183,"type":20},"2033-08-29",{"name":185,"class":104},"Tianjin Medical University",2,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":197,"conditions":198,"keywords":199,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":47},"100475296","cohort-primary-hyperparathyroidism-100475296","NCT05469087","Cohort Primary Hyperparathyroidism","Prospective Cohort Primary Hyperparathyroidism","CoHPT","Inclusion Criteria:\n\n• Age \\> 18\n\nExclusion Criteria:\n\n* Age \\\u003C 18\n* Pregnancy \u002F lactation\n* Adults underguardianship\n* Secondary\u002Ftertiary hyperparathyroidism\n* Multiple endocrine neoplasia",{"count":196,"type":20},403,"CoHPT is a prospective, monocentric, observational cohort including all patients diagnosed with primary hyperparathyroidism in Nantes University Hospital, aiming to study the outcomes associated with parathyroidectomy. Clinical and biochemical evaluation is performed at the inclusion, and 6, 12, 36 and 60 months. A biocollection is collected. The main hypotheses are that parathyroidectomy could improve cardiovascular, renal, bone, and cardiovascular outcomes along with quality of life.",[25],[68,200],"Parathyroidectomy","2025-08-29",{"date":203,"type":39},"2025-09-08",{"date":205,"type":39},"2016-03-31",{"date":207,"type":20},"2027-02-24",{"name":209,"class":104},"Nantes University Hospital",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":58,"phases":219,"briefSummary":221,"conditions":222,"keywords":223,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":47},"100603615","18f-choline-positron-emission-tomography---computed-tomography-compared-to-conventional-imaging-for-localizing-diseased-parathyroid-glands-in-primary-hyperparathyroidism-100603615","NCT07138820","18F-choline Positron-emission-tomography - Computed-tomography Compared to Conventional Imaging for Localizing Diseased Parathyroid Glands in Primary Hyperparathyroidism","18F-choline-PET-CT vs Ultrasonography and 99-technetium Sestamibi Scintigraphy in Preoperative Localization for pHPT - A Randomized Trial","Inclusion Criteria:\n\nProven primary hyperparathyroidism Indication for surgery Adult (\\>18 years)\n\nExclusion Criteria:\n\nInability to give informed consent Allergy to contrast Pregnancy and breastfeeding",{"count":218,"type":20},88,[220],"NA","The goal of this open, single-center, prospective, randomized, clinical study is to compare imaging with \\[18F\\]fluoromethyl-dimethyl-2-hydroxyethylammonium (18F-choline) positron-emission-tomography - computed-tomography, 18F-ch-PETCT, to conventional imaging with ultrasonography and sestamibi scintigraphy in localizing diseased parathyroid glands in patients diagnosed with primary hyperparathyroidism, pHPT. The question this study aims to answer is: can 18-F-ch-PET-CT more precisely localize diseased parathyroid glands in patients with pHPT before surgery? The objective of the study is to help improve precision in parathyroid surgery, thereby increasing cure rates, minimizing complications, and shortening operation times.",[25],[224,225,226,227,228],"surgery","positron emission tomography","scintigraphy","ultrasonography","primary hyperparathyroidism","2025-08-17",{"date":231,"type":39},"2025-08-24",{"date":233,"type":39},"2023-01-01",{"date":235,"type":20},"2027-02-28",{"name":237,"class":104},"Region Skane",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":15,"minAge":246,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":58,"phases":249,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":47},"100582151","phase-4-bisphosphonate-prior-to-parathyroidectomy-in-primary-hyperparathyroidism-100582151","NCT06859580","Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism","Bisphosphonate vs. Placebo Prior to Parathyroidectomy in Primary Hyperparathyroidisme: A Randomized, Double-blinded Placebo-controlled Trial","ZOLPHPT","Inclusion Criteria:\n\n1. Postmenopausal females or males \\> 50 years\n2. A diagnosis of hyperparathyroid hypercalcemia due to sporadic PHPT referred to PTX\n3. aBMD T-score ≤ -1 at total hip, femoral neck, or lumbar spine\n4. 25-hydroxyvitamin D ≥ 50 nmol\u002Fl prior to randomization\n5. Willingness to undergo PTX\n\nExclusion Criteria:\n\n1. Known or suspected familial ethology (e.g., MEN1 or 2)\n2. Estimated glomerular filtration rate \\\u003C 35 ml\u002Fmin\n3. Known allergy to bisphosphonates\n4. Planned or recent (within the last 3 months) major dental procedures (e.g., jaw surgery or tooth extraction)\n5. Chronic or acute disorders (e.g., rheumatoid arthritis, inflammatory bowel disease, cancer) or prior medications (e.g., lithium, glucocorticoids within the last year, antiresorptive or bone anabolic treatment within the last 3 years) known to affect bone metabolism.","50 Years",{"count":248,"type":20},140,[250],"PHASE4","This study is a randomized, double-blinded, placebo-controlled trial investigating the effects of zoledronic acid (ZOL) versus placebo in patients with primary hyperparathyroidism (PHPT) undergoing parathyroidectomy (PTX). PHPT is a common endocrine disorder associated with hypercalcemia, reduced bone mineral density (BMD), increased fracture risk, renal calcifications, and cardiovascular complications. While PTX remains the definitive treatment, the potential role of bisphosphonates in optimizing post-surgical outcomes remains unclear.\n\nThis trial aims to evaluate whether a single infusion of ZOL prior to PTX impacts bone health, cardiovascular parameters, and renal function one year post-surgery. The primary endpoint is the change in areal bone mineral density (aBMD) at the lumbar spine one year after PTX. Secondary endpoints include changes in aBMD at other skeletal sites, volumetric BMD, bone microarchitecture, bone turnover markers, coronary artery calcium score, arterial stiffness, and renal calcifications.\n\nA total of 140 postmenopausal women and men over 50 years with PHPT and low BMD will be enrolled and randomized to receive either ZOL or placebo 2-4 weeks before PTX. Participants will undergo extensive imaging, biochemical analysis, and cardiovascular assessments at baseline and one year post-surgery.\n\nThis study seeks to clarify whether ZOL improves post-surgical bone recovery or interferes with the natural bone remodeling process following PTX. Additionally, it will provide insight into the cardiovascular and renal effects of bisphosphonate therapy in PHPT patients. Findings may help guide treatment strategies for optimizing long-term skeletal and systemic health in this patient population.",[25],[254,255,256],"zoledronate","parathyroidectomy","placebo","2025-03-20",{"date":259,"type":39},"2025-03-25",{"date":261,"type":39},"2025-03-01",{"date":263,"type":20},"2028-02-01",{"name":265,"class":104},"University of Aarhus",{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":273,"targetDuration":16,"studyType":21,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":47},"100577929","is-intraoperative-pth-monitoring-obsolete-in-times-of-choline-petct-a-prospective-multicenter-cohort-study-to-determine-whether-the-regular-preoperative-use-of-choline-petct-scan-obviate-the-need-for-intraoperative-pth-measurement-in-patients-with-primary-hyperparathyreoidism-100577929","NCT06804681","Is Intraoperative PTH Monitoring Obsolete in Times of Choline PET\u002FCT? a Prospective Multicenter Cohort Study to Determine Whether the Regular Preoperative Use of Choline-PET\u002FCT Scan Obviate the Need for Intraoperative PTH-measurement in Patients with Primary Hyperparathyreoidism","Is Intraoperative PTH Monitoring Obsolete in Times of Choline PET\u002FCT?","Inclusion Criteria:\n\n* pHPT, preoperative Choline-PET, intraoperative PTH\n\nExclusion Criteria:\n\n* no consent",{"count":274,"type":20},1000,"In patients with primary hyperparathyreoidism (pHPT) in 80-90% only one of the four parathyroid glands has developed an autonomy and is causative for the disease. Localisation diagnostics are used to help identify the affected gland or glands in order to enable more focused surgical approaches and reduce morbidity of the surgery, as well as operative time. The gold standard for imaging in Germany and Austria are sonography and scintigraphy. If imaging is not conclusive, Choline-PET\u002FCT, which has been shown to have a higher specificity than the scintigraphy, especially for multiglandular disease, is performed mostly in Austria, but only on special indications in Germany. In Switzerland, as of 2023 the Choline-PET\u002FCT has replaced the scintigraphy and is routinely performed in patients with indication for parathyroidectomy in many hospitals.\n\nThe current S2k guideline recommends to perform an intraoperative PTH measurement before and 10 minutes after removal of the parathyroid gland in order to assess the success of the surgery. Due to the short half-life of PTH of around three minutes, a PTH drop of 50% or into the normal range within 10 minutes of removal of the suspected gland has a high sensitivity and specificity for cure. If PTH drop is inadequate, further gland exploration is performed. The intraoperative measurement of PTH is associated with waiting time in the OR and uncertainty if the next patient can be anesthetized, prolonging surgeries by 30-60 minutes depending on the local facilities. If the Choline-PET\u002FCT is sufficiently sensitive and specific in detecting both uni- and multiglandular disease, surgery according to Choline-PET\u002FCT findings could make waiting for intraoperative PTH drop unnecessary.\n\nThe aim of the study is to determine whether the regular use of Choline-PET\u002FCT can obviate the need for intraoperative PTH-measurement with the potential to shorten the length of parathyroid surgeries. This could save considerable costs and justify the regular use of Choline-PET\u002FCT.",[25],"2025-01-27",{"date":279,"type":39},"2025-02-03",{"date":281,"type":20},"2025-09",{"date":283,"type":20},"2028-09",{"name":285,"class":104},"University of Zurich",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":148,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":47},"100565883","diagnostic-performance-of-11ccholine-petct-in-the-preoperative-assessment-of-primary-hyperparathyroidism-100565883","NCT06647966","Diagnostic Performance of [11C]Choline PET\u002FCT In the Preoperative Assessment of Primary Hyperparathyroidism","Inclusion Criteria:\n\n* Patients with biochemically proven HPT, either through elevated serum levels of PTH or normal PTH despite hypercalcemia;\n* Age ≥ 18 years old;\n* \\[11C\\]CH PET\u002FCT for HPT before eventual surgery.\n\nExclusion Criteria:\n\n* Pregnancy or breast-feeding.",{"count":293,"type":20},200,"Primary hyperparathyroidism (HPT) ranks as the third most common endocrine disorder, characterized by excessive secretion of parathormone (PTH), a hormone crucial for regulating calcium and phosphorus metabolism within the body. The only cure for HPT is surgically removing the hyperfunctioning parathyroid tissue, both in symptomatic and asymptomatic settings. With the advance of preoperative medical imaging techniques, a paradigm shift has taken place in the surgical approach of this condition, evolving from an inpatient bilateral cervical exploration to an outpatient minimally invasive procedure, which has proved to be superior in outcome. Due to the small size of the glands, preoperative visualisation and localisation are mandatory for the surgeon. Several imaging methods have been researched for identifying hyperfunctioning parathyroid glands, including morphological, functional and hybrid techniques, with no clear agreement on the optimal imaging approach.The preoperative localization modalities available are ultrasonography; parathyroid scintigraphy using technetium \\[99mTc\\]Tc sestamibi (MIBI), multiphase multidetector 4D computed tomography (4DCT); magnetic resonance imaging; and recently, positron-emission tomography\u002Fcomputed tomography (PET\u002FCT) using 11C- and 18F-labelled radiotracers. While ultrasound and \\[99mTc\\]Tc-MIBI scintigraphy have been long used to diagnose and monitor patients with HPT, they can lead to numerous false negative results and therefore require additional examinations.Choline PET\u002FCT is steadily replacing conventional imaging in many centres, allowing for the localization of adenomas in three quarter of patients with negative previous imaging examinations, but is still considered a relatively new method. \\[11C\\]C-Choline (\\[11C\\]CH) PET\u002FCT is gradually gaining ground as a reliable method of localising HPT preoperatively, due to its fast uptake in hyperfunctioning parathyroid tissue, shorter acquisition time and lower radiation exposure compared to other nuclear medicine investigations and conventional methods. \\[11C\\]CH PET\u002FCT has been suggested to be superior in diagnostic performances, compared to other imaging methods, reaching sensitivities up to 98.9%.The aim of our retrospective, single centre study is to evaluate the diagnostic performances and the inter-observer agreement of \\[11C\\]CH PET\u002FCT for the preoperative detection of parathyroid adenomas in patients with suspected primary HPT.",[25],"2024-10-18",{"date":298,"type":39},"2024-10-22",{"date":300,"type":20},"2025-01",{"date":302,"type":20},"2025-12",{"name":304,"class":104},"IRCCS San Raffaele",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":58,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":47},"100357587","phase-4-calcitonin-pre-treatment-to-improve-spect-ct-sensitivity-100357587","NCT03935984","Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity","Improving the Sensitivity of Sestamibi SPECT-CT Parathyroid Scan with Calcitonin Pre-treatment for Primary Hyperparathyroidism","Inclusion Criteria:\n\n* Diagnosis of primary hyperparathyroidism\n* Non-localizing SPECT-CT performed within 365 days prior to consent to participate in study\n* Patient desires surgical intervention for treatment of PHPT\n* No contraindications to 99mTC-Sestamibi\n* No contraindications to treatment with calcitonin\n* Serum calcium level prior to non-localizing SPECT-CT is ≥10.5 mg\u002FdL\n* Patient consents to participate and undergo second SPECT-CT for purposes of research\n\nExclusion Criteria:\n\n* Previous surgery to the neck, including resection of parathyroid tissue, except where end organ damage is present and further surgical intervention is medically necessary\n* Contraindication to 99mTC-Sestamibi SPECT-CT as evidenced by allergic reaction or adverse event during index SPECT-CT\n* Allergy to calcitonin\n* Hypocalcemia (contraindication to calcitonin)\n* Vitamin D deficiency (contraindication to calcitonin)\n* Previous treatment with radioactive iodine\n* New prescription of thyroid medication (levothyroxine, armour thyroid tablets, etc. must be taken at time of index scan and research scan)\n* Lithium exposure within one year of SPECT-CT (index and research scans)\n* Secondary hyperparathyroidism\n* Benign familial hypocalciuric hypercalcemia\n* Known malignancy, particularly multiple endocrine neoplasia\n* New prescription of thiazide diuretic, (thiazide diuretic must have been taken at the time of index scan and second scan)\n* Currently taking calcium channel blockers\n* Pregnancy",{"count":313,"type":20},37,[250],"Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake\u002Fretention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.",[25,317],"Hypercalcemia","2024-09-16",{"date":320,"type":39},"2024-09-19",{"date":322,"type":39},"2019-05-29",{"date":324,"type":20},"2026-12-31",{"name":326,"class":104},"Joseph Sferra",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":112,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":371},"100556321","genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients-100556321","NCT06523582","Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients","Inclusion Criteria:\n\nAdult patients with a new or previous clinical diagnosis of any of the following conditions:\n\n* Isolated NENs with sporadic presentation, including bronchopulmonary NENs, gastrointestinal NENs, medullary thyroid carcinoma, pancreatic NENs, paragangliomas, pheochromocytomas, pituitary neuroendocrine tumors, and primary hyperparathyroidism.\n* Familial isolated NENs, including familial isolated pituitary adenoma, familial pheochromocytomas and paragangliomas, familial primary hyperparathyroidism, familial gastrointestinal stromal tumors and X-linked acrogigantism.\n* Clinical syndromes encompassing NENs, with familial or sporadic presentation, including Carney complex, Carney-Stratakis syndrome, Carney triad, Cowden syndrome, DICER1 syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia type 1, multiple endocrine neoplasia type 2, multiple endocrine neoplasia type 4, neurofibromatosis type 1, Pacak-Zhuang syndrome, paraganglioma, pheochromocytoma and pituitary adenoma syndrome, tuberous sclerosis complex, Von Hippel Lindau syndrome.\n\nExclusion criteria:\n\n* Age \\\u003C18 years.\n* Refusal to give informed consent.",{"count":334,"type":20},750,"Neuroendocrine neoplasms (NENs) are a heterogeneous group of lesions derived from cells with the ability to produce hormones that may arise from multiple different organs. Their clinical behavior is quite variable, encompassing both benign lesions and aggressive tumors that invade surrounding and\u002For distant structures. NENs may also cause serious morbidity due to hormone oversecretion. NENs are among the most frequently inherited human tumors, presenting either isolated or as part of syndromes in which a single patient or family develops multiple tumors. There are also non-inherited changes in the genetic information of the tumor cells that are potential targets for treatment. Both inherited and non-inherited DNA defects can be identified using modern routine genetic tests which, unfortunately, are not widely available in Mexico.\n\nThis project seeks to uncover the genetic defects causing NENs in a large cohort of Mexican patients, using three different methods for genetic testing. Adult individuals with various types of NENs from two reference hospitals in Mexico City will be invited to participate. After completing informed consent, blood and, if possible, tissue samples will be obtained from all participants. Clinical details, laboratory results, imaging studies, and histopathological data at disease presentation will be retrieved.\n\nAn initial screening will be performed by analyzing changes in the sequence of multiple genes that have been associated with the occurrence of NENs. In cases with negative screening, a specific method to assess changes in the number of copies of the same genes will also be employed. Finally, sequences of all DNA regions encoding information required to make proteins will be obtained in selected cases. Analyses will be carried out in blood and, if available, also in tumor tissue samples from study participants. Screening of additional family members will be offered.\n\nThis project will accurately describe the repertoire of specific defects causing NENs in the study population, and will likely uncover and characterize novel genetic associations. The results will contribute for a better understanding of the alterations within and outside known driver genes that shape syndromic presentations, tumor behaviors, and inheritance patterns in individuals with NENs. These data will contribute to improve the information on the molecular bases of NENs, including alterations that can be used as therapeutic targets.",[337,338,339,340,341,342,343,344,345,25,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361],"Neuroendocrine Neoplasm","Neuroendocrine Neoplasm of Gastrointestinal Tract","Neuroendocrine Neoplasm of Lung","Thymic Neuroendocrine Neoplasm","Neuroendocrine Tumor of Pancreas","Gastrointestinal Stromal Tumors","Medullary Thyroid Cancer","Paraganglioma","Pheochromocytoma","Pituitary Tumor","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Multiple Endocrine Neoplasia Type 4","Carney Complex","Carney Stratakis Dyad","Carney Triad","Cowden Syndrome","DICER1 Syndrome","Li-Fraumeni Syndrome","Lynch Syndrome","Von Hippel-Lindau Disease","Familial Isolated Pituitary Adenoma","X-Linked Acrogigantism","Neurofibromatosis 1","Tuberous Sclerosis","2024-07-22",{"date":364,"type":39},"2024-07-26",{"date":366,"type":39},"2022-08-03",{"date":368,"type":20},"2037-03-01",{"name":370,"class":104},"Universidad Nacional Autonoma de Mexico",3]